Latest Articlesddd
Immunotherapy for Cancer Blueprint Medicines Blueprint Medicines (BPMC) entered into a worldwide collaboration and exclusive license agreement …
First therapy to demonstrate statistically significant improvement in overall survival and induction response rate in a …
London, UK, 14 March 2016: GW Pharmaceuticals (GWPH), is a biopharmaceutical company focused on discovering, developing and …
The Diagnosed Dead Is Far from Dying Xoma (XOMA): Stock rallied following report announcing an upfront …
Of the Upcoming Game-Changing Actions THE EXPECTED FDA APPROVAL OF JAZZ DRUG DEFIBROTIDE On March 31, the FDA …
As we kept describing it, Illumina’s (ILMN) is the engine behind the biological revolution reflected in the current …
Prohost Letter #393 IMMUNOTHERAPY - PROHOST PORTFOLIO - NEW PICKS? - A Brief Reminder of the CAR T –TCR …
Preparing a Prohost Letter dedicated to immunotherapy and the firms that are behind the promising novel …
Agenus (AGEN) is a project in the making since the firm has decided to play an integral …
Exelixis’ (EXEL) quarterly results beat analysts’ expectations, which was the least of our concerns. The details of the …
Prohost Letter #392 February 28, 2016 - How could it be possible for any genius to make …
Baxalta (BXLT) and Precision BioSciences a genome editing company announced a global collaboration to develop a broad …
Recent Breakthrough Designated Products CANCER Acute Myeloid Leukemia PKC412 (midostaurin) developed by Novartis AG (NVS) is an oral, …
AMGEN AND OSTEOPOROSIS Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study of Romosozumab …
On February 4, 2015, we wrote an article titled, “Aerie Pharmaceuticals is speeding towards improving the …
Regulus Pharmaceuticals (RGLS) a biopharmaceutical company that discovers, designs and develop treatments targeting microRNAs announced interim results from one …
Gilead Sciences Gilead (GILD) Shareholders wouldn’t expect to watch short investors make billions of dollars going …
Yes. Dana-Farber Cancer Institute and Array Pharmaceuticals (ARRY) announced an immuno-oncology collaboration with potential applicability in a wide …
Prohost Letter #391 Frightened by the Market and Politicians’ Debates, Not the Drug Industry, Investors are Fleeing …
Incyte: A Good Company Facing Irrelevant Investors’ Reaction Incyte decided to stop an early ongoing trial …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
